LYMPHIR Drives Citius Oncology's Q2 with $5.6M Revenue, Positive Phase 1 Data
CTOR sits 96% above its 52-week low of $0.491 on light trading volume (0.1× avg).
Summary
Citius Pharmaceuticals (CTXR) reported its fiscal second quarter 2026 financial results, providing a comprehensive business update that significantly highlights its majority-owned subsidiary, Citius Oncology (CTOR). CTOR's recently launched product, LYMPHIR, generated $5.6 million in net revenue during its first four months of commercial sales, demonstrating strong initial traction with approximately 80% gross margins. The company also reported robust commercial progress, achieving near 100% payer coverage and 83% of target accounts on formulary or under review, alongside initial shipments to Europe. Furthermore, positive preliminary topline Phase 1 data for LYMPHIR in combination studies were announced, suggesting expanded platform potential. While CTOR's securing of up to $36.5 million in financing was previously disclosed on May 6th, this report confirms the capital infusion, which, combined with CTXR's $5 million offering, is expected to fund operations and LYMPHIR's commercial buildout. This comprehensive update provides critical positive news for Citius Oncology, addressing previous liquidity concerns with tangible revenue generation and strong commercial and clinical progress for its key asset.
At the time of this announcement, CTOR was trading at $0.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $85M. The 52-week trading range was $0.49 to $6.19. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.